- Home
- NEWP vs OMER Comparison
NEWP vs OMER Comparison
Compare NEWP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- OMER
- Stock Information
- Founded
- NEWP 1972
- OMER 1994
- Country
- NEWP Canada
- OMER United States
- Employees
- NEWP N/A
- OMER N/A
- Industry
- NEWP
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- OMER Health Care
- Exchange
- NEWP Nasdaq
- OMER Nasdaq
- Market Cap
- NEWP 363.2M
- OMER 304.9M
- IPO Year
- NEWP N/A
- OMER 2009
- Fundamental
- Price
- NEWP $2.17
- OMER $4.15
- Analyst Decision
- NEWP
- OMER Strong Buy
- Analyst Count
- NEWP 0
- OMER 5
- Target Price
- NEWP N/A
- OMER $18.00
- AVG Volume (30 Days)
- NEWP 434.0K
- OMER 931.1K
- Earning Date
- NEWP 11-12-2025
- OMER 11-12-2025
- Dividend Yield
- NEWP N/A
- OMER N/A
- EPS Growth
- NEWP N/A
- OMER N/A
- EPS
- NEWP N/A
- OMER N/A
- Revenue
- NEWP N/A
- OMER N/A
- Revenue This Year
- NEWP N/A
- OMER N/A
- Revenue Next Year
- NEWP N/A
- OMER $9,040.39
- P/E Ratio
- NEWP N/A
- OMER N/A
- Revenue Growth
- NEWP N/A
- OMER N/A
- 52 Week Low
- NEWP $0.93
- OMER $2.95
- 52 Week High
- NEWP $2.17
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- NEWP 69.94
- OMER 49.82
- Support Level
- NEWP $1.88
- OMER $4.07
- Resistance Level
- NEWP $2.15
- OMER $4.34
- Average True Range (ATR)
- NEWP 0.12
- OMER 0.18
- MACD
- NEWP 0.03
- OMER -0.03
- Stochastic Oscillator
- NEWP 99.02
- OMER 15.69
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.